Nearly a third of publicly-traded biotechs are trading for less than the cash on their balance sheets, says RTW's Wong

Dr. Rod Wong, managing partner and CIO of RTW Investments, which specializes in biotech, joins the 'Halftime Report' to discuss where he sees opportunity in the biotech space.